Healthcare of Ontario Pension Plan Trust Fund decreased its holdings in Bausch Health Cos Inc. (NYSE:BHC – Free Report) by 35.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,452,119 shares of the company’s stock after selling 4,547,881 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Bausch Health Cos were worth $58,742,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of BHC. Caitong International Asset Management Co. Ltd raised its position in Bausch Health Cos by 12,589.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after buying an additional 4,910 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Bausch Health Cos by 6,661.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after buying an additional 5,329 shares during the last quarter. Russell Investments Group Ltd. raised its position in Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after buying an additional 3,106 shares during the last quarter. Camelot Portfolios LLC bought a new stake in shares of Bausch Health Cos during the 4th quarter valued at about $59,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Bausch Health Cos during the 1st quarter valued at about $68,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on BHC shares. Royal Bank Of Canada reduced their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday, April 27th. Weiss Ratings lowered shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Wall Street Zen lowered shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Finally, Barclays reduced their price target on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 25th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $8.00.
Bausch Health Cos Price Performance
NYSE BHC opened at $5.06 on Monday. Bausch Health Cos Inc. has a 52 week low of $4.93 and a 52 week high of $8.69. The firm has a market capitalization of $1.89 billion, a P/E ratio of -1.56 and a beta of 0.40. The company has a quick ratio of 0.97, a current ratio of 1.32 and a debt-to-equity ratio of 54.68. The company has a 50-day moving average price of $5.46 and a 200-day moving average price of $5.99.
Bausch Health Cos (NYSE:BHC – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.37 billion. Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. Equities research analysts anticipate that Bausch Health Cos Inc. will post 4.08 earnings per share for the current year.
Insider Activity
In related news, Director Frank D. Lee sold 24,456 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total transaction of $132,796.08. Following the completion of the transaction, the director directly owned 49,339 shares in the company, valued at approximately $267,910.77. The trade was a 33.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.67% of the company’s stock.
Bausch Health Cos Company Profile
Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.
The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.
Featured Articles
- Five stocks we like better than Bausch Health Cos
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Cos Inc. (NYSE:BHC – Free Report).
Receive News & Ratings for Bausch Health Cos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Cos and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.gif){kind=logo}
